Product Information
TADALAFIL 2.5 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.1127 per EA under NDC 68382089610. Its NADAC has been published 52 times since Oct 8, 2025.
FDA first approved this application on Mar 26, 2019. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382089610
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TADALAFILApproval Type
Generic (ANDA)
FDA Application
ANDA206693FDA Approved
3/26/2019
TE Code
AB1
On Market Since
3/27/2019
Pharmacological Classes
Price Statistics
The NADAC for TADALAFIL 2.5 MG TABLET has been published 52 times since Oct 8, 2025, and over the history we have for it it has declined 10.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1127 per EA |
|---|---|
| All-time high | $0.1262 (Oct 15, 2025) |
| All-time low | $0.1127 (Sep 23, 2026) |
| 52-week high | $0.1262 |
| 52-week low | $0.1127 |
| Median price | $0.1202 |
| Average price | $0.1198 |
| Largest weekly change | -4.2% (May 20, 2026) |
| Weeks tracked | 52 |
| Tracking since | Oct 8, 2025 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tadalafil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 5 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TADALAFIL 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TADALAFIL 2.5 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.1127 per EA (NDC 68382089610), effective Sep 30, 2026.
How has the price of TADALAFIL 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for TADALAFIL 2.5 MG TABLET has declined 10.8%. It has been tracked across 52 weekly CMS publications since Oct 8, 2025.
What are the highest and lowest recorded NADAC prices for TADALAFIL 2.5 MG TABLET?
Since Oct 8, 2025, the NADAC for TADALAFIL 2.5 MG TABLET has ranged from a low of $0.1127 (Sep 23, 2026) to a high of $0.1262 (Oct 15, 2025), with a median of $0.1202 per EA.
Are there cheaper alternatives to TADALAFIL 2.5 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TADALAFIL 2.5 MG TABLET, is $0.1124 per EA — about 0% below TADALAFIL 2.5 MG TABLET.
Who manufactures TADALAFIL 2.5 MG TABLET?
TADALAFIL 2.5 MG TABLET (NDC 68382089610) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.